Searchable abstracts of presentations at key conferences in endocrinology

ea0026p269 | Pituitary | ECE2011

Macroprolactinomas and pregnancy: analysis of a 38-women cohort treated by dopamine agonists

Decoudier B , Raverot G , Ancelle D , Hecart A C , Borson-Chazot F , Delemer B

Pregnancy is associated with an increased risk of tumor growth in macroprolactinoma leading to discuss surgery in such cases.Objectives: Impact of pregnancy on prolactin secretion and tumor growth in a cohort of women with macroprolactinoma, including large tumors >20 mm, and medically treated.Methods: Retrospective study of all the women with macroprolactinomas diagnosed in two university hospitals, treated by dopamine agonist...

ea0020s12.3 | Growth factors and signaling networks in pituitary tumours | ECE2009

Molecular and histological prognostic markers in pituitary tumors

Trouillas J , Wierinckx A , Auger C , Jouanneau E , Jan M , Villeneuve L , Dantony E , Raverot G , Lachuer J

Although most pituitary tumors are benign, some are invasive or aggressive. In the absence of specific markers of malignancy, only tumors with metastases are considered malignant. Recently we identified a marker set of invasion, proliferation and aggressiveness in prolactin (PRL) tumors1. We will present the prognostic value of histological and molecular markers in PRL tumors and their usefulness in other types of pituitary tumors.Forty-five patients, 23...

ea0029p57 | Adrenal cortex | ICEECE2012

Reevaluation of the 4 mg intravenous dexamethasone suppression test for differentiation of Cushing’s disease from pseudo-Cushing’s syndrome

Nouvel M. , Rabilloud M. , Raverot V. , Pignard C. , Vouillarmet J. , Thivolet C. , Jouanneau E. , Chazot F Borson , Pugeat M. , Raverot G.

Context: Differentiating Cushing’s disease (CD) from pseudo-Cushing’s syndrome (PCS) is one of the most challenging problems since no biological test is yet perfect. Almost 30 years ago our group demonstrated the interest of 4 mg i.v. dexamethasone suppressing test (DST) to differentiate obese patients to CD.Objective: To reevaluate the diagnostic accuracy of the 4 mg i.v. DST in carefully selected patients with PCS and CD.<p class="abstext...

ea0029p1450 | Pituitary Clinical | ICEECE2012

Asymptomatic nonfunctioning pituitary macroadenomas take advantage of surgery

Dubourg J. , Messerer M. , Daniel R. , Bervini D. , Berhouma M. , Perrin G. , Iype G. , Chacko A. , Trouillas J. , Raverot G. , Jouanneau E.

Introduction: Pituitary incidentalomas (PIs) defined as pituitary tumors discovered by systematic neuroimaging constitute an increasingly clinical problem. Most of PIs are nonfunctioning tumors (NFPIs) with systematic investigation revealing visual and/or endocrinological impairment in some patients while others remained asymptomatic. If the therapeutic management is well codified for functioning PIs and symptomatic NFPIs, a debate still remain for asymptomatic NFPIs between s...

ea0026p218 | Pituitary | ECE2011

Macroprolactinomas in 38 children and adolescents: sex differences and long-term results of medical treatment

Ancelle D A , Raverot G R , Decoudier B D , Sulmont S V , Nicolino M N , Berlier P B , Borson-Chazot F B C , Delemer B D

Objectives: Long-term results of medical treatment of macroprolactinoma in children and adolescents (<20 years).Patients and methods: Retrospective analysis of all the cases of macroprolactinoma occurring in children and adolescents, medically treated in two university centers.Results: 38 patients, 25 girls 13 boys, age at diagnosis: 15.7±2.8 years (only two cases before 12 years). At diagnosis, 2/3 presented with headache...

ea0026p252 | Pituitary | ECE2011

Initial management and complications of Cushing disease (CD): a French multicenter study of 437 patients

Baudry C , Martinie M , Fathallah-Sahnoun M , Gatta-Cherifi B , Khalil R Bou , Guignat L , Gay E , Raverot G , Brue T , Tabarin A , Chabre O , Bertherat J

Introduction: CD is a rare disease. Our aim was to describe demographic and clinical characteristics together with initial management of patients with CD.Patients and methods: A retrospective analysis of 437 CD patients diagnosed between 1996 and 2009, followed in 5 tertiary centers (Bordeaux, Grenoble, Lyon, Marseille, Paris) was performed in the frame of the national program for rare diseases.Results: 347 (80%) were women. Mean a...

ea0029p993 | Growth hormone IGF axis - basic | ICEECE2012

Clinical characteristics and outcome of acromegaly induced by ectopic secretion of GHRH: a French nationwide series of 21 cases

Garby L. , Caron P. , Claustrat F. , Chanson P. , Tabarin A. , Rohmer V. , Arnault G. , Bonnet F. , Chabre O. , Christin Maitre S. , Du Boullay H. , Murat A. , Nakib I. , Sadoul J. , Sassolas G. , Claustrat B. , Raverot G. , Borson Chazot F.

Context: Ectopic GHRH secretion is a rare cause of acromegaly described mainly in isolated case reports.Setting: From the registry of the sole laboratory performing plasma GHRH assays in France, we identified cases of ectopic GHRH secretion presenting with acromegaly between 1983 and 2008.Patients: In total, 21 patients aged 14–77 years, from 12 French hospitals. Median GHRH was 548 ng/l (270–9779)....

ea0022p634 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Results of French collaborative evaluation (DEPHY-TC) in patients with suspected pituitary abnormalities after traumatic brain injury (TBI)

Courtois S , Nunes M L , Malezet M F , Morlet-Barla N , Borson-Chazot F , Peruzzi P , Tabarin A , Delarque M , Ciancia S , Boyer F , Cuny E , Delarque A , Delemer B , Richer E , Curallucci H , Di Nicola L , Raverot G

Study aim: Pituitary function evaluation in patients with traumatic brain injury (TBI).Subjects: One hundred and forty-six patients (49 female, 97 men, age: 31.9±16.2 years) recovered from moderate to severe TBI. Prospective follow up has been performed 3/6 and 12 months from TBI for 79 subjects. Retrospective evaluation (from 0.3 to 30 years) included 67 subjects selected in front of overt clinical features (obesity, fatigue, sexual disorders)....